美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Scribe Therapeutics, Inc.

31.73

-5.5200-14.82%

成交量：26.82萬

成交額：932.72萬

市值：5.58億

市盈率：-14.37

高：38.60

開：38.00

低：30.75

收：37.25

52周最高：39.60

52周最低：17.31

股本：1,757.74萬

流通股本：862.39萬

量比：0.71

換手率：3.11%

股息：- -

股息率：- -

每股收益(TTM):-2.2080

每股收益(LYR):-8.9776

淨資產收益率：--

總資產收益率：--

市淨率：-3.51

市盈率(LYR):-3.53

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Scribe Therapeutics, Inc.

交易所：

NASDAQ

成立時間：

2017

員工人數：

89

公司地址：

1150 Marina Village Pkwy,Alameda,California,United States

官網：

http://www.scribetx.com

郵編：

94501

電話：

傳真：

- -

簡介：

Scribe Therapeutics, Inc.於2017年6月30日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物技術公司，致力於研發專用的體內CRISPR技術，旨在通過疾病預防和持久的治療干預來延長健康壽命。公司正着力開發其技術，用於治療影響數百萬人的常見疾病，尤其關注那些存在巨大未滿足需求和沉重臨床負擔的流行疾病。公司專註於心血管和代謝疾病，其初期項目旨在解決動脈粥樣硬化性心血管疾病的關鍵驅動因素。公司正在設計基於CRISPR的基因藥物，力求使其具有良好的耐受性、有效性、持久性和可擴展性，從而將治療模式從癥狀驅動的干預和慢性病管理轉變為人群層面的預防。公司的主要候選產品利用其高度工程化的表觀遺傳沉默技術，旨在實現持久有效的LDL-C降低，且不會造成永久性基因改變。

董事

名稱

職位

Benjamin L. Oakes

President, Chief Executive Officer and Chairman of the Board and Director

Behzad Aghazadeh

Director

Carl L. Gordon

Director

James Watson

Director

Joshua Bleharski

Director

股東

名稱

職位

Benjamin L. Oakes

President, Chief Executive Officer and Chairman of the Board and Director

Svetlana Lucas

Chief Operating Officer

David L. Parrot

Chief Financial Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/SCTX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SCTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","market":"US","secType":"STK","nameCN":"Scribe Therapeutics, Inc.","latestPrice":31.73,"timestamp":1787686024051,"preClose":37.25,"halted":0,"volume":268207,"delay":0,"changeRate":-0.14818791946308724,"floatShares":8623940,"shares":17577400,"eps":-2.208,"marketStatus":"交易中","change":-5.52,"latestTime":"08-25 15:27:15 EDT","open":38,"high":38.5999,"low":30.7514,"amount":9327154.562685002,"amplitude":0.210698,"askPrice":31.73,"askSize":100,"bidPrice":30.37,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.208,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1784865600000,"exchange":"NASDAQ","adjPreClose":37.25,"preHourTrading":{"tag":"盘前","latestPrice":38,"preClose":37.25,"latestTime":"09:29 EDT","volume":1824,"amount":70546.82976000001,"timestamp":1787664599915,"change":0.75,"changeRate":0.020134,"amplitude":0.048322},"postHourTrading":{"tag":"盘后","latestPrice":37.69,"preClose":37.25,"latestTime":"19:41 EDT","volume":3278,"amount":123003.144,"timestamp":1787614875176,"change":0.44,"changeRate":0.011812,"amplitude":0.050738},"volumeRatio":0.707575},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCTX\",,,,,undefined,":{"symbol":"SCTX","floatShares":8623940,"roa":"--","roe":"--","lyrEps":-8.977559,"volumeRatio":0.707575,"shares":17577400,"dividePrice":0,"high":38.5999,"amplitude":0.210698,"preClose":37.25,"low":30.7514,"week52Low":17.305,"pbRate":"-3.51","psRate":"15.37","week52High":39.6,"institutionHeld":0,"latestPrice":31.73,"eps":-2.208,"divideRate":0,"volume":268207,"delay":0,"ttmEps":-2.208,"open":38,"prevYearClose":15,"prevWeekClose":34.13,"prevMonthClose":19.48,"prevQuarterClose":15,"fiveDayClose":27.11,"twentyDayClose":18.06,"sixtyDayClose":15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1787544000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SCTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SCTX","date":"2026-08-24","current":-15.307971,"percent":0,"low":-18.019633,"twenty":-13.664932,"median":-11.417362,"eighty":-10.069453,"high":-6.340558,"avg":-11.955615,"sd":2.809018,"marketCap":643841494},"quantilePoints":[{"date":"2026-07-24","current":-7.393791,"twenty":-7.183144,"median":-6.867174,"eighty":-6.551205,"marketCap":264180150},{"date":"2026-07-31","current":-10.770598,"twenty":-10.0156,"median":-9.614342,"eighty":-7.393791,"marketCap":384833474},{"date":"2026-08-07","current":-13.41573,"twenty":-11.647029,"median":-10.284865,"eighty":-9.535147,"marketCap":479344048},{"date":"2026-08-14","current":-10.754759,"twenty":-12.565698,"median":-10.885431,"eighty":-9.693538,"marketCap":384267542},{"date":"2026-08-21","current":-17.333272,"twenty":-13.41573,"median":-11.187695,"eighty":-10.0156,"marketCap":619317792},{"date":"2026-08-24","current":-18.019633,"twenty":-13.664932,"median":-11.417362,"eighty":-10.069453,"marketCap":643841494}],"updateTime":1787679988764},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":642070737,"yearFounded":2017,"employeeNum":89,"address":"1150 Marina Village Pkwy,Alameda,California,United States","zipCode":"94501","officePhone":"510 626 8587","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.scribetx.com","stockEarnings":[{"period":"1week","weight":0.7579},{"period":"1month","weight":0.7206},{"period":"3month","weight":1.4833},{"period":"ytd","weight":1.4833}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Scribe Therapeutics, Inc.於2017年6月30日根據特拉華州法律註冊成立。該公司是一家臨床階段的生物技術公司，致力於研發專用的體內CRISPR技術，旨在通過疾病預防和持久的治療干預來延長健康壽命。公司正着力開發其技術，用於治療影響數百萬人的常見疾病，尤其關注那些存在巨大未滿足需求和沉重臨床負擔的流行疾病。公司專註於心血管和代謝疾病，其初期項目旨在解決動脈粥樣硬化性心血管疾病的關鍵驅動因素。公司正在設計基於CRISPR的基因藥物，力求使其具有良好的耐受性、有效性、持久性和可擴展性，從而將治療模式從癥狀驅動的干預和慢性病管理轉變為人群層面的預防。公司的主要候選產品利用其高度工程化的表觀遺傳沉默技術，旨在實現持久有效的LDL-C降低，且不會造成永久性基因改變。","exchange":"NASDAQ","name":"Scribe Therapeutics, Inc.","nameEN":"Scribe Therapeutics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SCTX\",market:\"US\",,,undefined,":{"directors":[{"name":"Benjamin L. Oakes","position":"President, Chief Executive Officer and Chairman of the Board and Director"},{"name":"Behzad Aghazadeh","position":"Director"},{"name":"Carl L. Gordon","position":"Director"},{"name":"James Watson","position":"Director"},{"name":"Joshua Bleharski","position":"Director"}],"executives":[{"name":"Benjamin L. Oakes","position":"President, Chief Executive Officer and Chairman of the Board and Director"},{"name":"Svetlana Lucas","position":"Chief Operating Officer"},{"name":"David L. Parrot","position":"Chief Financial Officer"}]}}}